RxDoctor Payments DataLook up a doctor →

Uri Guefen, MD

General Practice · Chula Vista, CANPI 1275646333

Payments from drug & device makers

$78,810in general payments, 2019–2025

Across 661 payments — averaging $119.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$32K
  • Amgen$21K
  • Amarin Pharma, Inc.$13K
  • AstraZeneca$5K
  • Boston Scientific$1K
  • Novo Nordisk$1K
  • plus $5K from 29 others

What the payments were for

  • Consulting fees$1,2502%
  • Speaking & faculty fees$54,32069%
  • Travel & lodging$4,9446%
  • Food & beverage$18,27123%
  • Education$120%
  • Entertainment$130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$78,810 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$13,047
Medicare patients
31
Services billed
168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$56,116
CreonLipase/Protease/Amylase16$55,767
Repatha SureclickEvolocumab49$28,519
FarxigaDapagliflozin Propanediol18$25,065
JanuviaSitagliptin Phosphate25$24,141
Icosapent Ethyl51$12,287
Repatha SyringeEvolocumab20$12,059
VascepaIcosapent Ethyl18$7,969
Repatha PushtronexEvolocumab11$6,435
Atorvastatin Calcium137$1,542
Pregabalin14$970
Celecoxib15$820
Albuterol Sulfate HfaAlbuterol Sulfate26$806
Tamsulosin Hcl41$562
Rosuvastatin Calcium27$549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,229$56,11639 claims
AbbVieCreon$32,423$55,76716 claims
AstraZenecaFarxiga$4,902$25,06518 claims
MerckJanuvia$256$24,14125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.

Other general practice in Chula Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →